Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction

J Butler, SZ Abildstrøm, BA Borlaug, MJ Davies… - Journal of the American …, 2023 - jacc.org
Background Many therapies for heart failure (HF) have shown differential impact across the
spectrum of left ventricular ejection fraction (LVEF). Objectives In this prespecified analysis …

Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials

S Verma, J Butler, BA Borlaug, M Davies… - Journal of the American …, 2024 - jacc.org
Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

[HTML][HTML] Semaglutide in patients with heart failure with preserved ejection fraction and obesity

MN Kosiborod, SZ Abildstrøm, BA Borlaug… - … England Journal of …, 2023 - Mass Medical Soc
Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program

M Schou, MC Petrie, BA Borlaug, J Butler… - Journal of the American …, 2024 - jacc.org
Abstract Background In the Semaglutide Treatment Effect in People with obesity and HFpEF
(STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms …

Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype

MN Kosiborod, SZ Abildstrøm, BA Borlaug, J Butler… - Heart Failure, 2023 - jacc.org
Background The majority of patients with heart failure with preserved ejection fraction
(HFpEF) have the obesity phenotype, but no therapies specifically targeting obesity in …

Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the …

MN Kosiborod, S Verma, BA Borlaug, J Butler… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF)
and obesity experience a high burden of symptoms and functional impairment, and a poor …

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

BA Borlaug, DW Kitzman, MJ Davies, S Rasmussen… - Nature medicine, 2023 - nature.com
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise
function and reduced body weight in patients with obesity phenotype of heart failure and …

Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

SJ Shah, K Sharma, BA Borlaug, J Butler… - European Heart …, 2024 - academic.oup.com
Abstract Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide
resulted in multiple beneficial effects in patients with obesity-related heart failure with …

Semaglutide in patients with obesity-related heart failure and type 2 diabetes

MN Kosiborod, MC Petrie, BA Borlaug… - … England Journal of …, 2024 - Mass Medical Soc
Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure

SD Solomon, JW Ostrominski, X Wang, SJ Shah… - Journal of the American …, 2024 - jacc.org
Background Obesity is associated with adverse cardiac remodeling and is a key driver for
the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) …